These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 9419193)

  • 1. Immunogenicity of live attenuated SA14-14-2 Japanese encephalitis vaccine--a comparison of 1- and 3-month immunization schedules.
    Tsai TF; Yu YX; Jia LL; Putvatana R; Zhang R; Wang S; Halstead SB
    J Infect Dis; 1998 Jan; 177(1):221-3. PubMed ID: 9419193
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chimeric live, attenuated vaccine against Japanese encephalitis (ChimeriVax-JE): phase 2 clinical trials for safety and immunogenicity, effect of vaccine dose and schedule, and memory response to challenge with inactivated Japanese encephalitis antigen.
    Monath TP; Guirakhoo F; Nichols R; Yoksan S; Schrader R; Murphy C; Blum P; Woodward S; McCarthy K; Mathis D; Johnson C; Bedford P
    J Infect Dis; 2003 Oct; 188(8):1213-30. PubMed ID: 14551893
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunogenicity of a Japanese encephalitis chimeric virus vaccine as a booster dose after primary vaccination with SA14-14-2 vaccine in Thai children.
    Janewongwirot P; Puthanakit T; Anugulruengkitt S; Jantarabenjakul W; Phasomsap C; Chumket S; Yoksan S; Pancharoen C
    Vaccine; 2016 Oct; 34(44):5279-5283. PubMed ID: 27628323
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized study of the immunogenicity and safety of Japanese encephalitis chimeric virus vaccine (JE-CV) in comparison with SA14-14-2 vaccine in children in the Republic of Korea.
    Kim DS; Houillon G; Jang GC; Cha SH; Choi SH; Lee J; Kim HM; Kim JH; Kang JH; Kim JH; Kim KH; Kim HS; Bang J; Naimi Z; Bosch-Castells V; Boaz M; Bouckenooghe A
    Hum Vaccin Immunother; 2014; 10(9):2656-63. PubMed ID: 25483480
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunizing children aged 9 to 15 months with live attenuated SA14-14-2 Japanese encephalitis vaccine in Thailand.
    Chotpitayasunondh T; Sohn YM; Yoksan S; Min J; Ohrr H
    J Med Assoc Thai; 2011 Aug; 94 Suppl 3():S195-203. PubMed ID: 22043776
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Primary immunization of infants and toddlers in Thailand with Japanese encephalitis chimeric virus vaccine in comparison with SA14-14-2: a randomized study of immunogenicity and safety.
    Feroldi E; Pancharoen C; Kosalaraksa P; Chokephaibulkit K; Boaz M; Meric C; Hutagalung Y; Bouckenooghe A
    Pediatr Infect Dis J; 2014 Jun; 33(6):643-9. PubMed ID: 24717964
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A 5-year follow-up of antibody response in children vaccinated with single dose of live attenuated SA14-14-2 Japanese encephalitis vaccine: immunogenicity and anamnestic responses.
    Sohn YM; Tandan JB; Yoksan S; Ji M; Ohrr H
    Vaccine; 2008 Mar; 26(13):1638-43. PubMed ID: 18294743
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunogenicity and safety of inactivated chromatographically purified Vero cell-derived Japanese encephalitis vaccine in Thai children.
    Chanthavanich P; Limkittikul K; Sirivichayakul C; Chokejindachai W; Hattasingh W; Pengsaa K; Surangsrirat S; Srisuwannaporn T; Kaewma B; Yoksan S; Jun G; Zhumu B
    Hum Vaccin Immunother; 2018 Apr; 14(4):900-905. PubMed ID: 29227177
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Primary and booster immune responses to SA14-14-2 Japanese encephalitis vaccine in Korean infants.
    Sohn YM; Park MS; Rho HO; Chandler LJ; Shope RE; Tsai TF
    Vaccine; 1999 May; 17(18):2259-64. PubMed ID: 10403593
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety of a live-attenuated Japanese encephalitis virus vaccine (SA14-14-2) for children.
    Xin YY; Ming ZG; Peng GY; Jian A; Min LH
    Am J Trop Med Hyg; 1988 Aug; 39(2):214-7. PubMed ID: 2841880
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term follow-up of Japanese encephalitis chimeric virus vaccine: Immune responses in children.
    Chokephaibulkit K; Sirivichayakul C; Thisyakorn U; Pancharoen C; Boaz M; Bouckenooghe A; Feroldi E
    Vaccine; 2016 Nov; 34(46):5664-5669. PubMed ID: 27686833
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sero-Molecular Epidemiology of Japanese Encephalitis in Zhejiang, an Eastern Province of China.
    Pan JR; Yan JY; Zhou JY; Tang XW; He HQ; Xie RH; Mao HY; Zhang YJ; Xie SY
    PLoS Negl Trop Dis; 2016 Aug; 10(8):e0004936. PubMed ID: 27560360
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and immunogenicity of live-attenuated Japanese encephalitis SA 14-14-2 vaccine co-administered with measles vaccine in 9-month-old infants in Sri Lanka.
    Wijesinghe PR; Abeysinghe MR; Yoksan S; Yao Y; Zhou B; Zhang L; Yaich M; Neuzil KM; Victor JC
    Vaccine; 2014 Aug; 32(37):4751-7. PubMed ID: 24951871
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity of experimental live attenuated Japanese encephalitis vaccine viruses and comparison with wild-type strains using monoclonal and polyclonal antibodies.
    Sil BK; Wills MR; Cao JX; Sharda R; Islam MA; Stagg DJ; Jennings AD; Gibson CA; Barrett AD
    Vaccine; 1992; 10(5):329-33. PubMed ID: 1315470
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity of a Live Attenuated Chimeric Japanese Encephalitis Vaccine as a Booster Dose After Primary Vaccination With Live Attenuated SA14-14-2 Vaccine: A Phase IV Study in Thai Children.
    Sricharoenchai S; Lapphra K; Chuenkitmongkol S; Phongsamart W; Bouckenooghe A; Wittawatmongkol O; Rungmaitree S; Chokephaibulkit K
    Pediatr Infect Dis J; 2017 Feb; 36(2):e45-e47. PubMed ID: 27846060
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the immunogenicity and safety of measles vaccine administered alone or with live, attenuated Japanese encephalitis SA 14-14-2 vaccine in Philippine infants.
    Gatchalian S; Yao Y; Zhou B; Zhang L; Yoksan S; Kelly K; Neuzil KM; Yaïch M; Jacobson J
    Vaccine; 2008 Apr; 26(18):2234-41. PubMed ID: 18394765
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Immunogenicity and Safety of the Live-attenuated SA 14-14-2 Japanese Encephalitis Vaccine Given with a Two-dose Primary Schedule in Children.
    Kwon HJ; Lee SY; Kim KH; Kim DS; Cha SH; Jo DS; Kang JH
    J Korean Med Sci; 2015 May; 30(5):612-6. PubMed ID: 25931793
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity, genetic stability, and protective efficacy of a recombinant, chimeric yellow fever-Japanese encephalitis virus (ChimeriVax-JE) as a live, attenuated vaccine candidate against Japanese encephalitis.
    Guirakhoo F; Zhang ZX; Chambers TJ; Delagrave S; Arroyo J; Barrett AD; Monath TP
    Virology; 1999 May; 257(2):363-72. PubMed ID: 10329547
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term immunogenicity of an initial booster dose of an inactivated, Vero cell culture-derived Japanese encephalitis vaccine (JE-VC) and the safety and immunogenicity of a second JE-VC booster dose in children previously vaccinated with an inactivated, mouse brain-derived Japanese encephalitis vaccine.
    Yun KW; Lee HJ; Park JY; Cho HK; Kim YJ; Kim KH; Kim NH; Hong YJ; Kim DH; Kim HM; Cha SH
    Vaccine; 2018 Mar; 36(11):1398-1404. PubMed ID: 29429815
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Homologous and heterologous neutralization antibody responses after immunization with Japanese encephalitis vaccine among Taiwan children.
    Ku CC; King CC; Lin CY; Hsu HC; Chen LY; Yueh YY; Chang GJ
    J Med Virol; 1994 Oct; 44(2):122-31. PubMed ID: 7852952
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.